![Asian stocks rise as rate cut bets build; Japan tests record highs](https://i-invdn-com.investing.com/news/LYNXNPEC0Q0L5_S.jpg)
Please try another search
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Gregory Batcheller | 66 | 2011 | Executive Chairman of the Board |
Thomas Eldered | 63 | 2022 | Director |
Lars Hedbys | 66 | 2021 | Independent Director |
Hans-Joachim Simons | 61 | 2022 | Director |
Maarten de Chateau | 61 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review